Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Association of tumor burden with the efficacy of PD-(L)1 inhibitors for treatment-naive advanced non-small-cell lung cancer
PubMed Similar studies Analyze with GEO2R
High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway
PubMed Full text in PMC Similar studies
The expression profiles of exosomal miRNAs associated with response to anti-PD-1/PD-L1 monotherapy in advanced NSCLC patients.
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer (NSCLC)
PubMed Similar studies
Multi-omic and spatial dissection of immunotherapy response groups in NSCLC
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on